Drug Profile
Socazolimab - Lee's Pharmaceutical/Sorrento Therapeutics
Alternative Names: PD-L1 monoclonal antibody - Lee's Pharmaceutical /Sorrento Therapeutics; STI-1014; STI-A1014; ZKAB-001Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Developer Lee's Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Cervical cancer
- Phase III Osteosarcoma; Small cell lung cancer
- Phase I/II Malignant melanoma; Oesophageal cancer; Urogenital cancer
- No development reported Biliary cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Biliary-cancer(Combination therapy, Adjuvant therapy) in China (IV)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Urogenital-cancer(Combination therapy, Late-stage disease) in China (IV, Injection)
- 19 Dec 2023 Registered for Cervical cancer (Metastatic disease, Recurrent) in China (IV) - First global approval